Skip to NavigationSkip to content

Pharmafile.com's weekly COVID-19 news round-up

Published on 10/06/20 at 11:46am
Photo by CDC

Hydroxychloroquine as a potential coronavirus treatment continues to be a contentious issue, as a new study led by researchers at the University of Minnesota finds it does not protect people from COVID-19, while The Lancet’s editors have expressed their concerns over a paper published in their journal that said hydroxychloroquine and chloroquine was dangerous for use in COVID-19 patients.

In other news, the Trump administration has selected the finalists for the COVID-19 vaccine it is seeking to make widely available by the end of the year, while Kings College London has launched a clinical trial to investigate how effective a formulation of ibuoprofen is in reducing respiratory failure in coronavirus patients.

1. Kings College London launches trial investigating the effectiveness of ibuprofen in COVID-19 patientsPublished 03/06/20

Kings College London has launched a clinical trial to investigate how effective a formulation of ibuoprofen is in reducing respiratory failure in coronavirus patients.

2. Trump’s Operation Warp Speed selects Pfizer, Merck, AstraZeneca and Moderna as vaccine finalistsPublished 04/06/20

The Trump administration has selected the finalists for the COVID-19 vaccine it is seeking to make widely available by the end of the year.

3. Lancet expresses concern over published hydroxychloroquine and chloroquine paperPublished 03/06/20

The Lancet’s editors have expressed their concerns over a paper published in their journal that said hydroxychloroquine and chloroquine was dangerous for use in COVID-19 patients.

4. Hydroxychloroquine does not work as a preventative against COVID-19, new study findsPublished 04/06/20

The malaria drug hydroxychloroquine does not protect people from COVID-19, according to a new study led by researchers at the University of Minnesota.

5. Australian Taskforce recommends Gilead's remdesivir for routine use in the country's COVID-19 patientsPublished 05/06/20

Australia could be set to follow the decisions of other nations around the world in officially licensing Gilead’s antiviral therapy remdesivir in the treatment of COVID-19, after the country’s National COVID-19 Clinical Evidence Taskforce, a specialist team bringing together some of Australia’s leading health groups, has given its recommendation for routine use of the drug.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches